Biomarkers of dementia in obstructive sleep apnea

Epidemiologic and mechanistic evidence is increasingly supporting the notion that obstructive sleep apnea is a risk factor for dementia. Hence, the identification of patients at risk of cognitive decline due to obstructive sleep apnea may significantly improve preventive strategies and treatment decisionmaking. Cerebrospinal fluid and blood biomarkers obtained through genomic, proteomic and metabolomic approaches are improving the ability to predict incident dementia. Therefore, fluid biomarkers have the potential to predict vulnerability to neurodegeneration in individuals with obstructive sleep apnea, as well as deepen our understanding of pathophysiological processes linking obstructive sleep apnea and dementia. Many fluid biomarkers linked to Alzheimer’s disease and vascular dementia show abnormal levels in individuals with obstructive sleep apnea, suggesting that these conditions share common underlying mechanisms, including amyloid and tau protein neuropathology, inflammation, oxidative stress, and metabolic disturbances. Markers of these processes include amyloid-β, tau proteins, inflammatory cytokines, acute-phase proteins, antioxydants and oxidized products, homocysteine and clusterin (apolipoprotein J). Thus, these biomarkers may have the ability to identify adults with obstructive sleep apnea at high risk of dementia and provide an opportunity for therapeutic intervention. Large cohort studies are necessary to establish a specific fluid biomarker panel linking obstructive sleep apnea to dementia risk

Cerebral white matter diffusion properties and free‐water with obstructive sleep apnea severity in older adults

Characterizing the effects of obstructive sleep apnea (OSA) on the aging brain could be key in our understanding of neurodegeneration in this population. Our objective was to assess white matter properties in newly diagnosed and untreated adults with mild to severe OSA. Sixty‐five adults aged 55 to 85 were recruited and divided into three groups: control (apnea‐hypopnea index ≤5/hr; n = 18; 65.2 ± 7.2 years old), mild (>5 to ≤15 hr; n = 27; 64.2 ± 5.3 years old) and moderate to severe OSA (>15/hr; n = 20; 65.2 ± 5.5 years old). Diffusion tensor imaging metrics (fractional anisotropy (FA), axial diffusivity (AD), radial diffusivity, and mean diffusivity) were compared between groups with Tract‐Based Spatial Statistics within the white matter skeleton created by the technique. Groups were also compared for white matter hyperintensities volume and the free‐water (FW) fraction. Compared with controls, mild OSA participants showed widespread areas of lower diffusivity (p < .05 corrected) and lower FW fraction (p < .05). Participants with moderate to severe OSA showed lower AD in the corpus callosum compared with controls (p < .05 corrected). No between‐group differences were observed for FA or white matter hyperintensities. Lower white matter diffusivity metrics is especially marked in mild OSA, suggesting that even the milder form may lead to detrimental outcomes. In moderate to severe OSA, competing pathological responses might have led to partial normalization of diffusion metrics

Obstructive sleep apnea and the risk of cognitive decline in older adults

Obstructive sleep apnea causes intermittent hypoxia and sleep fragmentation and affects at least 20% of individuals after the age of 65. There is accumulating evidence that obstructive sleep apnea may impact brain structure and function. Recent cohort studies suggest that it is a risk factor for stroke, mild cognitive impairment and Alzheimer’s disease. Because prevention through treatment of risk factors is currently the main intervention for reducing the incidence of dementia, how obstructive sleep apnea affects brain health and whether its treatment can slow neurodegeneration are relevant questions. This Perspective Article presents the most recent findings on the neurocognitive consequences of obstructive sleep apnea in the elderly. We focus on the aging brain and the link between obstructive sleep apnea, brain health, cognitive decline and dementia. We present how new discoveries from animal models, human sleep experiments, and Alzheimer’s disease biomarkers point to an active role of disturbed sleep in dementia pathogenesis. We show preliminary data on how sex, genetics, physical exercise and cognitive reserve can strengthen or weaken the association between obstructive sleep apnea and dementia. We present preliminary results of obstructive sleep apnea treatment, which can slow, stop or reverse neurodegenerative processes accentuated by obstructive sleep apnea, even in individuals already affected by a neurodegenerative disease. We propose future research directions that include studies on mild/moderate untreated obstructive sleep apnea, the evaluation of continuous positive airway pressure treatment to slow neurodegeneration and follow-up studies of older patients that measure predictors/markers of dementi